GLA
AZN icon

Good Life Advisors’s AstraZeneca AZN Stock Holding History

Good Life Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,533
Closed -$239K – 492
2024
Q3 		$239K Buy
+1,533
New +$247K 0.01% 518
2023
Q3 		– Sell
-2,574
Closed -$368K – 416
2023
Q2 		$368K Hold
2,574
– – 0.04% 273
2023
Q1 		$357K Sell
2,574
-397
-13% -$53.4K 0.05% 266
2022
Q4 		$403K Sell
2,971
-203
-6% -$25.5K 0.06% 226
2022
Q3 		$348K Buy
3,174
+32
+1% +$4.06K 0.05% 234
2022
Q2 		$415K Sell
3,142
-100
-3% -$13.1K 0.06% 219
2022
Q1 		$430K Sell
3,242
-116
-3% -$13.9K 0.05% 231
2021
Q4 		$391K Buy
3,358
+17
+0.5% +$2K 0.05% 245
2021
Q3 		$401K Buy
+3,341
New +$389K 0.05% 232

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Good Life Advisors's AZN Position: Q4 2024 in Review

Good Life Advisors sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 1,533 shares — an estimated $239K sold.

Good Life Advisors first reported a position in AZN in Q3 2021 and held it in 9 quarters. The position peaked at $430K in Q1 2022. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Good Life Advisors reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
  • Good Life Advisors sold 1,533 AstraZeneca shares in Q4 2024, an estimated $239K.
  • Good Life Advisors first reported a position in AstraZeneca in Q3 2021 and held it in 9 quarters.
  • Good Life Advisors's AstraZeneca position peaked at $430K in Q1 2022.
  • 1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Good Life Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.